NCT06979375招募中2 期
Phase 2, Multicentre, Randomised, Double-blind, Placebo-controlled Safety and Efficacy Study of CDR132L on Reverse Cardiac Remodelling in Participants With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 200
- 试验地点
- 170
- 主要终点
- Main Phase: Change in normalised microRNA-132-3p (miR-132)
研究概览
简要总结
This study will look into how CDR132L (a potential new medicine) works on the structure and function of the heart in people living with heart failure. Participants will either get CDR132L or placebo (a medicine which has no effect on the body), which treatment the participants get is decided by chance. The study will last for about 60 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 40 Years 至 84 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 40-84 years (both inclusive) at the time of signing the informed consent.
- •Documented symptomatic heart failure (HF) diagnosed greater than or equal to (≥) 180 days prior to screening with at least weekly need for oral diuretic treatment, and New York Heart Association class II-III at screening.
- •Clinically stable and on optimized doses and unchanged drug classes of guideline-directed HF therapy ≥ 45 days prior to randomisation.
- •Left ventricular ejection fraction (LVEF) less than (<) 50 percent (%) as assessed by echocardiography at screening, measured by central laboratory.
- •Left ventricular hypertrophy or left ventricular dilatation assessed by echocardiography at screening measured by central laboratory with any of the following:
- •LVMi greater than (>)88 g/m^2 for female participants and >102 g/m^2 for male participants using the truncated ellipsoid method.
- •LVMi >95 g/m^2 for female participants and >115 g/m^2 for male participants, using the linear method (cube formula).
- •Left ventricular end-diastolic diameter indexed to body surface area (LVEDDi) >3.1 cm/m^2 for female participants and >3.0 cm/m^2 for male participants.
- •Body mass index 18.5-40 kilogram per meter square (kg/m^2) (both inclusive) and body weight less than or equal to (≤) 140 kilogram (kg). Body mass index is calculated in the electronic case report form based on height and body weight at the screening visit (visit 1).
- •N-terminal pro B-type natriuretic peptide (NT-proBNP) ≥ 300 picograms per milliliter (pg/mL); NT-proBNP ≥600 pg/mL if atrial fibrillation/flutter is present at time of screening, measured by central laboratory.
排除标准
- •Estimated Glomerular Filtration Rate (eGFR) less than (<) 30 milliliter/minute/ 1.73-meter square (mL/min/1.73 m^2) at time of screening, measured by central laboratory.
- •Participants with an episode of acute kidney failure or acute kidney injury, at the discretion of the investigator,within 90 days prior to randomisation.
- •Myocardial infarction, unstable angina pectoris or HF hospitalization within 30 days prior to screening.
- •Participants receiving intravenous HF medications within 45 days prior to randomisation.
- •Planned coronary revascularization, pacemaker/cardioverter-defibrillator/cardiac resynchronization therapy (CRT) implantation, ablation of cardiac arrythmias or valve repair/replacement at the time of randomisation.
- •Stroke or transient ischemic attack within 12 months prior to randomisation.
- •Participants with potential disruption of the blood-brain barrier (e.g., multiple sclerosis), in the opinion of the investigator.
- •Known history of severe liver disease and/or alanine aminotransferase or aspartate aminotransferase greater than (>) 2.5x upper limit of normal at screening, measured by central laboratory.
- •Known genetic (or highly suspected due to family history) cause of increased cardiac mass (including dilated cardiomyopathy, Fabry disease and likely pathogenic or pathogenic variants within hypertrophic cardiomyopathy (HCM).
- •Participants with suspected or diagnosed cardiac amyloidosis or sarcoidosis.
研究组 & 干预措施
CDR132L + SoC
Experimental
Participants will receive intravenous infusion of CDR132L once every 4 weeks for 48 weeks. Participants will also continue their individually adapted guideline-directed Standard of care (SoC) therapy for heart failure.
干预措施: CDR132L (Drug)
Placebo + SoC
Placebo Comparator
Participants will receive intravenous infusion of placebo once every 4 weeks for 48 weeks. Participants will also continue their individually adapted guideline-directed Standard of care (SoC) therapy for heart failure.
干预措施: Placebo (Drug)
结局指标
主要结局
Main Phase: Change in normalised microRNA-132-3p (miR-132)
时间窗: From baseline to week 24
Ratio to baseline
次要结局
- Main Phase: Change in composite Z-score based on the 3 outcome measures: LVEDVi; LVESVi; NT-proBNP(From baseline to week 24)
- Main Phase: Number of adverse events(From baseline to week 24)
- Extension Phase: Number of adverse events(From baseline to week 60)
研究者
研究点 (170)
Loading locations...
相似试验
已完成
2 期
Multicenter Study to Evaluate CRx-102 vs. Each of Its Components to Treat Active Rheumatoid ArthritisRheumatoid ArthritisNCT00551707Zalicus51
终止
2 期
CRx-102 Osteoarthritis Multicenter Evaluation TrialKnee OsteoarthritisNCT00521989Zalicus279
招募中
3 期
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARBFSGSNCT05183646Dimerix Bioscience Pty Ltd286
已完成
2 期
A Safety and Efficacy Study of DRL-17822, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Patients With Abnormal Cholesterol LevelsType II HyperlipidemiaNCT01388816Dr. Reddy's Laboratories Limited176
已完成
2 期
A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic GastroparesisDiabetic GastroparesisNCT05832151CinDome Pharma, Inc.382